SCHEMBL23609264

SCHEMBL23609264

c1ccc(-c2ccc(NC3CCCCC3)cc2NCCn2cncn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
CYP19A1 P11511 4/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 1/20 0.36
NR2F2 P24468 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 6/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 1/20 0.35
ALDH1A1 P00352 7/20 0.35
CYP3A4 P08684 5/20 0.35
TSHR P16473 5/20 0.35
HSD17B10 Q99714 5/20 0.35
ALOX15 P16050 3/20 0.35
HPGD P15428 4/20 0.34
MAPK1 P28482 3/20 0.34
TP53 P04637 2/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23609161 0.82 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23608983 0.80 CYP19A1 (0.43) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23609143 0.79 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23609006 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23579458 0.77 SMN1; SMN2 (0.46) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23609386 0.77 SMN1; SMN2 (0.46) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23608977 0.77 PKM (0.43) SMN1; SMN2HTTMEN1KMT2ANPC1
SCHEMBL23609019 0.76 CSNK2A2 (0.46) SMN1; SMN2HTTCYP19A1MEN1KMT2A
SCHEMBL23608951 0.75 CSNK2A2 (0.44) MEN1KMT2AKDM4EMAPTLMNA
SCHEMBL23608891 0.74 FPR3 (0.40) CYP19A1MEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 SMN1; SMN2 243/4885HTT 549/4885CYP19A1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.